Great Basin Initiates Clinical Trial for Shiga Toxin-Producing E. coli Molecular Diagnostic Test
Diagnostic Test Will Also Detect Serotype E. coli O157:H7
SALT LAKE CITY, Feb. 12, 2015 /PRNewswire/ -- Great Basin Scientific, Inc. (NASDAQ: GBSN), today announced it has initiated a clinical trial for its Shiga toxin-producing E. coli (STEC) diagnostic test. The Great Basin STEC diagnostic test will also detect serotype E. coli O157:H7.
This is the third clinical trial the Company has initiated since July 2014. In December of 2014, the Company initiated a clinical trial for its Staph ID/R (identification/resistance) blood sepsis diagnostic test. In 2012 the Company launched its FDA-cleared Toxigenic C. diff diagnostic test.
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease. More information can be found on the company's website at www.gbscience.com.
Forward-Looking Statements
Certain statements in this press release may be deemed to be forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history or losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.
Media Contact:
Tony Russo, Ph.D. or Todd Davenport, Ph.D.
Russo Partners, LLC
212.845.4251
[email protected]
[email protected]
Investor Relations Contact:
Bob Yedid
ICR
646.277.1250
[email protected]
SOURCE Great Basin Scientific, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article